Eurocine Vaccines AB (publ) (”Eurocine Vaccines) hereby publishes the interim report for July 2021 to December 2022. Below is a summary of the report. The…
Eurocine Vaccines AB (publ) (”Eurocine Vaccines) publicerar härmed delårsrapport för juli 2021 till mars 2022. Nedan följer en kort sammanfattning av rapporten. Fullständig rapport finns…
Eurocine Vaccines AB (publ) (”Eurocine Vaccines”) nyttjandeperiod för teckningsoptioner av serie TO 4 slutade den 28 mars 2022. Ärendet har registrerats på Bolagsverket och omvandling…
Connecting Early Stage Products with Capital & Channel Partners The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors and strategic channel partners. RESIRead…
Small Companies´ Days 2022 in collaboration with the Swedish Shareholders´ Association CEO Hans Arwidsson will present the Company, the building of a vaccine portfolio andRead…
Eurocine Vaccines, a dedicated and returning participant, will join the Biotechgate Digital Partnering to meet with people in the vaccine area, both new connections and already establishedRead…
